Morrison & Foerster's global co-head of M&A and London head of corporate has left the firm.

Graeme Sloan exited in March, he confirmed, to join a life sciences client which is currently developing a treatment for COVID-19.

He has joined Oxford-based biopharmaceutical company Izana Bioscience in a temporary position, after almost five years at MoFo.

Sloan said: "While I take the time needed to decide on my next move, I am helping Izana Bioscience which was one of my clients at MoFo. It has technology that may help in the treatment of patients with COVID-19."

Izana Bioscience is currently developing an antibody for the treatment of COVID-19, according to the company's website.

Sloan joined Morrison & Foerster in 2015 as global co-chair of M&A after almost a decade at Latham & Watkins, where he also served as chair the firm's global M&A practice. Among other major mandates at MoFo, he advised Tokyo-based technology giant SoftBank on its £24 billion acquisition of U.K. smartphone chip designer ARM.

Morrison & Foerster said in a comment: "We can confirm that Graeme Sloan left the firm at the end of March to pursue other interests and opportunities. We are grateful for Graeme's assistance in building the corporate department in our London office, and we wish him well in his future endeavours."

Earlier this month, the firm added Freshfields Bruckhaus Deringer's former U.S. head of M&A and global transactions, Mitchell Presser, to its New York office.

|

Read more:

Morrison & Foerster Posts Double-Digit Revenue Growth